PFDN2

PFDN2 is a β subunit of the URI prefoldin-like heterohexameric chaperone complex, which contains two α subunits (URI and STAP1) and four β subunits (PFDN2, PFDN6, and PFDN4r) (PMID:30484155). Beyond its structural role in this complex, PFDN2 functions as a transcriptional and signaling regulator across several cellular contexts. In retinal ganglion cells it acts upstream of γ-synuclein (SNCG), as knockdown reduces Sncg expression and places PFDN2 within the same regulatory pathway (PMID:26663874, PMID:27933535). In gastric cancer, PFDN2 drives cell cycle progression through a PFDN2–hnRNPD–MYBL2 axis, facilitating nuclear translocation of hnRNPD to upregulate MYBL2 transcription (PMID:37538116). In colorectal cancer, PFDN2 physically binds PYCR2 and stabilizes it against proteasome-dependent degradation, thereby activating Wnt/β-catenin signaling to promote proliferation and migration (PMID:41656306). The mechanistic relationship between PFDN2's chaperone-complex membership and these context-specific regulatory activities has not been characterized in the available corpus.

1. 2016 Medium

   Established that PFDN2 functions as an upstream regulator of a specific transcriptional target, moving it beyond a presumed generic chaperone role into a defined gene-regulatory pathway in neurons.

   Evidence eQTL mapping plus siRNA knockdown in primary murine retinal ganglion cells with IHC co-localization

   PMID:26663874

   Open questions at the time

   • Mechanism by which PFDN2 controls SNCG expression is undefined
   • No evidence whether this is direct or via the chaperone complex
2. 2017 Medium

   Confirmed the PFDN2→SNCG epistatic relationship in an independent purified RGC system, solidifying the upstream placement of PFDN2.

   Evidence siRNA knockdown in flow-sorted primary RGCs with qPCR readout

   PMID:27933535

   Open questions at the time

   • Does not establish a molecular mechanism linking PFDN2 to SNCG transcription
3. 2018 Medium

   Defined PFDN2 as a β subunit of the URI prefoldin-like heterohexameric chaperone complex, establishing its structural assignment.

   Evidence Immunoprecipitation / complex reconstitution in mammalian cells (review citing original IP data)

   PMID:30484155

   Open questions at the time

   • Chaperone substrates of the complex not defined here
   • Link between complex membership and PFDN2's regulatory functions unestablished
4. 2020 Low

   Catalogued PFDN2 among interactors of NEK10 and of cardiac syndecan-2, raising candidate roles in DNA-damage signaling and cardiac signaling that remain unvalidated.

   Evidence Co-IP/AP coupled to LC-MS/MS in cells and rat ventricle with HEK293 verification

   PMID:32368190 PMID:32984315

   Open questions at the time

   • Single AP-MS identifications without reciprocal validation
   • No functional characterization of either interaction specific to PFDN2
5. 2023 Medium

   Placed PFDN2 within a cancer cell-cycle pathway by defining a PFDN2–hnRNPD–MYBL2 transcriptional axis, providing a mechanistic route from PFDN2 to proliferative gene expression.

   Evidence Gain/loss-of-function, nuclear fractionation, reporter assays, and co-IP in gastric cancer cells

   PMID:37538116

   Open questions at the time

   • How PFDN2 promotes hnRNPD nuclear translocation is unresolved
   • Single lab, single cancer type
6. 2026 Medium

   Demonstrated a protein-stabilization mechanism whereby PFDN2 binds PYCR2 and protects it from proteasomal degradation to activate Wnt/β-catenin signaling, connecting PFDN2 to oncogenic signaling in colorectal cancer.

   Evidence Co-IP, immunofluorescence, cycloheximide chase, MG132 rescue, TOP/FOPflash reporter and rescue assays

   PMID:41656306

   Open questions at the time

   • Mechanism by which PFDN2 limits PYCR2 degradation (e.g., shielding from ubiquitination) not resolved
   • Whether this depends on the chaperone complex is unknown
7. 2026 Low

   Proposed a tumor-suppressive, extracellular role for plasma PFDN2 via interaction with monocyte CD64 in head and neck cancer, contrasting with its intracellular pro-proliferative roles.

   Evidence Mendelian randomization, molecular docking/dynamics, scRNA-seq, and scTenifoldKnk virtual knockout

   PMID:41884853

   Open questions at the time

   • Interaction supported only by computational docking/simulation with no direct biochemical binding assay
   • Extracellular localization and secretion of PFDN2 not biochemically established

• Whether PFDN2's chaperone-complex function mechanistically underlies its diverse transcriptional, protein-stabilization, and signaling activities remains unresolved.
• No unifying mechanistic model connecting chaperone role to gene-regulatory roles
• No structural data on PFDN2 substrate or partner binding